{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:06:36Z","timestamp":1791975996835,"version":"4.4.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019559","name":"Carl von Ossietzky Universit\u00e4t Oldenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019559","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objective<\/jats:title>\n                <jats:p>Impulse control disorders (ICD), psychosis and delirium are part of the spectrum of behavioural changes associated with Parkinson\u2019s disease (PD). The diagnostic and therapeutic management of these rather complex neuropsychiatric conditions has been updated in the clinical guideline by the German Society of Neurology (DGN).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Recommendations are based on a systematic literature reviews, other relevant guidelines and expert opinion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients receiving dopamine agonists (DA) therapy should be informed about the symptoms and risks of an ICD and should be routinely screened for ICD symptoms. In the presence of an ICD, DA should be reduced or discontinued and psychotherapeutic treatment may be considered. Non-oral therapies (levodopa\/carbidopa intestinal gel infusion or deep brain stimulation) may also be an option for appropriate candidates. Psychosis in PD often has a gradual onset. Cognitive and affective disorders, psychiatric and medical comorbidities as well as polypharmacy are risk factors for a psychosis. Non-pharmacological treatments should be implemented as soon as possible and anti-parkinsonian medications should be adjusted\/reduced if feasible. For psychosis associated with PD, quetiapine or clozapine should be used on an as-needed basis and for as short a time as is necessary, with safety monitoring. Delirium in PD may be underdiagnosed due to an overlap with chronic neuropsychiatric features of PD. Although transient by definition, delirium in PD can lead to permanent cognitive decline, motor impairment and increased mortality. Management of delirium includes pharmacological and non-pharmacological interventions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The updated guideline encompasses the evidence-based diagnostic, non-pharmacological and pharmacological management of ICD, psychosis and delirium in PD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12576-x","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T12:05:30Z","timestamp":1721822730000},"page":"7402-7421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations\u00a0- guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-3474","authenticated-orcid":false,"given":"Karsten","family":"Witt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"van Eimeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkomiet","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ebersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the German Parkinson\u2019s Guideline Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"B\u00e4hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Becktepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Buhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Ceballos-Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Cla\u00dfen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ebersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Eggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"van Eimeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fanciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kristin","family":"Folkerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Gausepohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkomiet","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hilker-Roggendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"H\u00f6llerhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Hopfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Kalbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kassubek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Klietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"K\u00f6glsperger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Krack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krismer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Kuhlenb\u00e4umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Liepelt-Scarfone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lingor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Loewenbr\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"L\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Lorenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Maa\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Maetzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"Mollenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Outeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"P\u00f6tter-Nerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Reetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Rie\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons","family":"Schnitzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Seppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Sixel-D\u00f6ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Storch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"T\u00f6nges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trenkwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"van Eimeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"W\u00e4chter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Warnecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Woitalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Zeuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas L.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"12576_CR1","first-page":"365","volume":"91","author":"Y Agid","year":"2003","unstructured":"Agid Y, Arnulf I, Bejjani P, Bloch F, Bonnet AM, Damier P, Dubois B, Francois C, Houeto JL, Iacono D, Karachi C, Mesnage V, Messouak O, Vidailhet M, Welter ML, Yelnik J (2003) Parkinson\u2019s disease is a neuropsychiatric disorder. Adv Neurol 91:365\u2013370","journal-title":"Adv Neurol"},{"key":"12576_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/gps.5270","volume":"35","author":"RA Lawson","year":"2020","unstructured":"Lawson RA, Richardson SJ, Yarnall AJ, Burn DJ, Allan LM (2020) Identifying delirium in Parkinson disease: a pilot study. Int J Geriatr Psychiatry 35:547\u2013552. https:\/\/doi.org\/10.1002\/gps.5270","journal-title":"Int J Geriatr Psychiatry"},{"key":"12576_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/mds.25679","volume":"29","author":"KS Goerlich-Dobre","year":"2014","unstructured":"Goerlich-Dobre KS, Probst C, Winter L, Witt K, Deuschl G, M\u00f6ller B, van Eimeren T (2014) Alexithymia-an independent risk factor for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord 29:214\u2013220. https:\/\/doi.org\/10.1002\/mds.25679","journal-title":"Mov Disord"},{"key":"12576_CR4","unstructured":"H\u00f6glinger G, Trenkwalder C, et al. (2023) Parkinson-Krankheit, S2k-Leitlinie, 2023. In: Deutsche Gesellschaft f\u00fcr Neurologie (ed) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. https:\/\/dgn.org\/leitlinie\/parkinson-krankheit. Accessed 25 March 2024"},{"key":"12576_CR5","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften \/ Working Group of the Scientific Medical Societies, AWMF-Regelwerk Leitlinien. https:\/\/www.awmf.org\/regelwerk\/stufenklassifikationen. Accessed 02 Jul 2024"},{"key":"12576_CR6","doi-asserted-by":"crossref","unstructured":"Maschke M et al (2020) Delir und Verwirrtheitszust\u00e4nde inklusive Alkoholentzugsdelir, S1-Leitlinie. in: Deutsche Gesellschaft f\u00fcr Neurologie (ed), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Online: www.dgn.org\/leitlinien. Accessed 22 April 2024","DOI":"10.1007\/s42451-021-00302-0"},{"key":"12576_CR7","unstructured":"DGPPN e.V. (ed) (2019) f\u00fcr die Leitliniengruppe: S3-Leitlinie Schizophrenie. Langfassung (2019) Version 1.0, zuletzt ge\u00e4ndert am 15. https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/038-009.htm"},{"key":"12576_CR8","unstructured":"Deutsche Gesellschaft f\u00fcr Neurologie (DGN)(ed) (2016) S3-Leitlinie \u201eIdiopathisches Parkinson-Syndrom\u201c. https:\/\/register.awmf.org\/assets\/guidelines\/030-010k_S3_Parkinson_Syndrome_Idiopathisch_2016-06-abgelaufen.pdf"},{"key":"12576_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00406-006-0668-0","volume":"256","author":"B Dell'Osso","year":"2006","unstructured":"Dell\u2019Osso B, Altamura AC, Allen A, Marazziti D, Hollander E (2006) Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci 256:464\u2013475. https:\/\/doi.org\/10.1007\/s00406-006-0668-0","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"12576_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589\u2013595. https:\/\/doi.org\/10.1001\/archneurol.2010.65","journal-title":"Arch Neurol"},{"key":"12576_CR11","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1212\/wnl.0000000000005816","volume":"91","author":"JC Corvol","year":"2018","unstructured":"Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Lee PC, Brice A, Vidailhet M, Elbaz A (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91:e189\u2013e201. https:\/\/doi.org\/10.1212\/wnl.0000000000005816","journal-title":"Neurology"},{"key":"12576_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/nyas.13356","volume":"1394","author":"KM Nautiyal","year":"2017","unstructured":"Nautiyal KM, Okuda M, Hen R, Blanco C (2017) Gambling disorder: an integrative review of animal and human studies. Ann N Y Acad Sci 1394:106\u2013127. https:\/\/doi.org\/10.1111\/nyas.13356","journal-title":"Ann N Y Acad Sci"},{"key":"12576_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1348\/000712605x53533","volume":"96","author":"H Dittmar","year":"2005","unstructured":"Dittmar H (2005) Compulsive buying\u2013a growing concern? An examination of gender, age, and endorsement of materialistic values as predictors. Br J Psychol 96:467\u2013491. https:\/\/doi.org\/10.1348\/000712605x53533","journal-title":"Br J Psychol"},{"key":"12576_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1196\/annals.1444.006","volume":"1142","author":"SY Lim","year":"2008","unstructured":"Lim SY, Evans AH, Miyasaki JM (2008) Impulse control and related disorders in Parkinson\u2019s disease: review. Ann N Y Acad Sci 1142:85\u2013107. https:\/\/doi.org\/10.1196\/annals.1444.006","journal-title":"Ann N Y Acad Sci"},{"key":"12576_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/mds.20757","volume":"21","author":"MJ Nirenberg","year":"2006","unstructured":"Nirenberg MJ, Waters C (2006) Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21:524\u2013529. https:\/\/doi.org\/10.1002\/mds.20757","journal-title":"Mov Disord"},{"key":"12576_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068718","volume":"379","author":"D Weintraub","year":"2022","unstructured":"Weintraub D, Aarsland D, Biundo R, Dobkin R, Goldman J, Lewis S (2022) Management of psychiatric and cognitive complications in Parkinson\u2019s disease. BMJ 379:e068718. https:\/\/doi.org\/10.1136\/bmj-2021-068718","journal-title":"BMJ"},{"key":"12576_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","volume":"68","author":"G Giovannoni","year":"2000","unstructured":"Giovannoni G, O\u2019Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423\u2013428. https:\/\/doi.org\/10.1136\/jnnp.68.4.423","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12576_CR18","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/ene.13078","volume":"23","author":"A Antonini","year":"2016","unstructured":"Antonini A, Chaudhuri KR, Boroojerdi B, Asgharnejad M, Bauer L, Grieger F, Weintraub D (2016) Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. Eur J Neurol 23:1556\u20131565. https:\/\/doi.org\/10.1111\/ene.13078","journal-title":"Eur J Neurol"},{"key":"12576_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3233\/JPD-150597","volume":"5","author":"A Alvarado-Bolanos","year":"2015","unstructured":"Alvarado-Bolanos A, Cervantes-Arriaga A, Rodriguez-Violante M, Llorens-Arenas R, Calderon-Fajardo H, Millan-Cepeda R, Leal-Ortega R, Estrada-Bellmann I, Zuniga-Ramirez C (2015) Impact of neuropsychiatric symptoms on the quality of life of subjects with Parkinson\u2019s disease. J Parkinsons Dis 5:541\u2013548. https:\/\/doi.org\/10.3233\/JPD-150597","journal-title":"J Parkinsons Dis"},{"key":"12576_CR20","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"24","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord 24:1461\u20131467. https:\/\/doi.org\/10.1002\/mds.22571","journal-title":"Mov Disord"},{"key":"12576_CR21","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s00415-014-7299-6","volume":"261","author":"CC Probst","year":"2014","unstructured":"Probst CC, Winter LM, M\u00f6ller B, Weber H, Weintraub D, Witt K, Deuschl G, Katzenschlager R, van Eimeren T (2014) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease (QUIP) and the QUIP-rating scale in a German speaking sample. J Neurol 261:936\u2013942. https:\/\/doi.org\/10.1007\/s00415-014-7299-6","journal-title":"J Neurol"},{"key":"12576_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2021.100113","volume":"5","author":"A Hall","year":"2021","unstructured":"Hall A, Weaver SR, Compton LJ, Byblow WD, Jenkinson N, MacDonald HJ (2021) Dopamine genetic risk score predicts impulse control behaviors in Parkinson\u2019s disease. Clin Park Relat Disord 5:100113. https:\/\/doi.org\/10.1016\/j.prdoa.2021.100113","journal-title":"Clin Park Relat Disord"},{"key":"12576_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fnbeh.2014.00196","volume":"8","author":"CA Clark","year":"2014","unstructured":"Clark CA, Dagher A (2014) The role of dopamine in risk taking: a specific look at Parkinson\u2019s disease and gambling. Front Behav Neurosci 8:196. https:\/\/doi.org\/10.3389\/fnbeh.2014.00196","journal-title":"Front Behav Neurosci"},{"key":"12576_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/sj.npp.1301153","volume":"32","author":"R Cools","year":"2007","unstructured":"Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW (2007) L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson\u2019s disease. Neuropsychopharmacology 32:180\u2013189. https:\/\/doi.org\/10.1038\/sj.npp.1301153","journal-title":"Neuropsychopharmacology"},{"key":"12576_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1006\/nimg.2001.1031","volume":"15","author":"MP Paulus","year":"2002","unstructured":"Paulus MP, Hozack N, Frank L, Brown GG (2002) Error rate and outcome predictability affect neural activation in prefrontal cortex and anterior cingulate during decision-making. Neuroimage 15:836\u2013846. https:\/\/doi.org\/10.1006\/nimg.2001.1031","journal-title":"Neuroimage"},{"key":"12576_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.parkreldis.2015.10.013","volume":"24","author":"A Tessitore","year":"2016","unstructured":"Tessitore A, Santangelo G, De Micco R, Vitale C, Giordano A, Raimo S, Corbo D, Amboni M, Barone P, Tedeschi G (2016) Cortical thickness changes in patients with Parkinson\u2019s disease and impulse control disorders. Parkinsonism Relat Disord 24:119\u2013125. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.10.013","journal-title":"Parkinsonism Relat Disord"},{"key":"12576_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/82959","volume":"4","author":"J O'Doherty","year":"2001","unstructured":"O\u2019Doherty J, Kringelbach ML, Rolls ET, Hornak J, Andrews C (2001) Abstract reward and punishment representations in the human orbitofrontal cortex. Nat Neurosci 4:95\u2013102. https:\/\/doi.org\/10.1038\/82959","journal-title":"Nat Neurosci"},{"issue":"Suppl 1","key":"12576_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neuropharm.2004.07.019","volume":"47","author":"ND Volkow","year":"2004","unstructured":"Volkow ND, Fowler JS, Wang GJ (2004) The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47(Suppl 1):3\u201313. https:\/\/doi.org\/10.1016\/j.neuropharm.2004.07.019","journal-title":"Neuropharmacology"},{"key":"12576_CR29","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11910-013-0386-8","volume":"13","author":"CC Probst","year":"2013","unstructured":"Probst CC, van Eimeren T (2013) The functional anatomy of impulse control disorders. Curr Neurol Neurosci Rep 13:386. https:\/\/doi.org\/10.1007\/s11910-013-0386-8","journal-title":"Curr Neurol Neurosci Rep"},{"key":"12576_CR30","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.22164","volume":"68","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68:963\u2013968. https:\/\/doi.org\/10.1002\/ana.22164","journal-title":"Ann Neurol"},{"key":"12576_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.nrleng.2022.04.002","volume":"38","author":"A Contreras Chicote","year":"2023","unstructured":"Contreras Chicote A, Velilla Alonso G, Mas Serrano M, Grandas Perez F (2023) New-onset impulse control disorders after treatment with levodopa-carbidopa intestinal gel in Parkinson\u2019s disease. Neurologia (Engl Ed) 38:220\u2013221. https:\/\/doi.org\/10.1016\/j.nrleng.2022.04.002","journal-title":"Neurologia (Engl Ed)"},{"key":"12576_CR32","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I (2014) Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85:840\u2013844. https:\/\/doi.org\/10.1136\/jnnp-2013-306787","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12576_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/pds.4986","volume":"29","author":"U Gungabissoon","year":"2020","unstructured":"Gungabissoon U, Kirichek O, El Baou C, Galwey N (2020) Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson\u2019s disease. Pharmacoepidemiol Drug Saf 29:591\u2013598. https:\/\/doi.org\/10.1002\/pds.4986","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"12576_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1590\/0004-282X20140212","volume":"73","author":"FE Micheli","year":"2015","unstructured":"Micheli FE, Giugni JC, Espinosa ME, Calvo DS, Raina GB (2015) Piribedil and pathological gambling in six parkinsonian patients. Arq Neuropsiquiatr 73:115\u2013118. https:\/\/doi.org\/10.1590\/0004-282X20140212","journal-title":"Arq Neuropsiquiatr"},{"key":"12576_CR35","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/ene.13034","volume":"23","author":"A Rizos","year":"2016","unstructured":"Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, Henriksen T, Falup-Pecurariu C, Silverdale M, Durner G, Rokenes Karlsen K, Grilo M, Odin P, Chaudhuri KR, Europar, the IN-M-PDSG (2016) A European multicentre survey of impulse control behaviours in Parkinson\u2019s disease patients treated with short\u2014and long-acting dopamine agonists. Eur J Neurol 23:1255\u20131261. https:\/\/doi.org\/10.1111\/ene.13034","journal-title":"Eur J Neurol"},{"key":"12576_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mds.21770","volume":"23","author":"E Mamikonyan","year":"2008","unstructured":"Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB, Weintraub D (2008) Long-term follow-up of impulse control disorders in Parkinson\u2019s disease. Mov Disord 23:75\u201380. https:\/\/doi.org\/10.1002\/mds.21770","journal-title":"Mov Disord"},{"key":"12576_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/WNF.0000000000000091","volume":"38","author":"A Todorova","year":"2015","unstructured":"Todorova A, Samuel M, Brown RG, Chaudhuri KR (2015) Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years\u2019 follow-up. Clin Neuropharmacol 38:132\u2013134. https:\/\/doi.org\/10.1097\/WNF.0000000000000091","journal-title":"Clin Neuropharmacol"},{"key":"12576_CR38","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/mds.25636","volume":"28","author":"MJ Catalan","year":"2013","unstructured":"Catalan MJ, de Pablo-Fernandez E, Villanueva C, Fernandez-Diez S, Lapena-Montero T, Garcia-Ramos R, Lopez-Valdes E (2013) Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson\u2019s disease. Mov Disord 28:2007\u20132010. https:\/\/doi.org\/10.1002\/mds.25636","journal-title":"Mov Disord"},{"key":"12576_CR39","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00415-018-8803-1","volume":"265","author":"MJ Catalan","year":"2018","unstructured":"Catalan MJ, Molina-Arjona JA, Mir P, Cubo E, Arbelo JM, Martinez-Martin P, Group ES (2018) Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease. J Neurol 265:1279\u20131287. https:\/\/doi.org\/10.1007\/s00415-018-8803-1","journal-title":"J Neurol"},{"key":"12576_CR40","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","volume":"83","author":"K Papay","year":"2014","unstructured":"Papay K, Xie SX, Stern M, Hurtig H, Siderowf A, Duda JE, Minger J, Weintraub D (2014) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 83:826\u2013833. https:\/\/doi.org\/10.1212\/WNL.0000000000000729","journal-title":"Neurology"},{"key":"12576_CR41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ana.22029","volume":"68","author":"A Thomas","year":"2010","unstructured":"Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68:400\u2013404. https:\/\/doi.org\/10.1002\/ana.22029","journal-title":"Ann Neurol"},{"key":"12576_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/mds.23964","volume":"27","author":"RA Walsh","year":"2012","unstructured":"Walsh RA, Lang AE (2012) Multiple impulse control disorders developing in Parkinson\u2019s disease after initiation of amantadine. Mov Disord 27:326. https:\/\/doi.org\/10.1002\/mds.23964","journal-title":"Mov Disord"},{"key":"12576_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrneurol.2010.206","volume":"7","author":"E Beal","year":"2011","unstructured":"Beal E (2011) Parkinson disease: amantadine administration is associated with impulse control disorders in PD. Nat Rev Neurol 7:62. https:\/\/doi.org\/10.1038\/nrneurol.2010.206","journal-title":"Nat Rev Neurol"},{"key":"12576_CR44","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00415-010-5603-7","volume":"257","author":"PE Bermejo","year":"2010","unstructured":"Bermejo PE, Ruiz-Huete C, Anciones B (2010) Zonisamide in managing impulse control disorders in Parkinson\u2019s disease. J Neurol 257:1682\u20131685. https:\/\/doi.org\/10.1007\/s00415-010-5603-7","journal-title":"J Neurol"},{"key":"12576_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mdc3.12167","volume":"2","author":"J Liang","year":"2015","unstructured":"Liang J, Groves M, Shanker VL (2015) Clozapine treatment for impulse control disorders in Parkinson\u2019s disease patients: a case series. Mov Disord Clin Pract 2:283\u2013285. https:\/\/doi.org\/10.1002\/mdc3.12167","journal-title":"Mov Disord Clin Pract"},{"key":"12576_CR46","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1007\/s00213-015-4048-1","volume":"232","author":"NA Bonfils","year":"2015","unstructured":"Bonfils NA, Benyamina A, Aubin HJ, Luquiens A (2015) Clozapine use for refractory impulse control disorders in Parkinson\u2019s disease: a case report. Psychopharmacology 232:3677\u20133679. https:\/\/doi.org\/10.1007\/s00213-015-4048-1","journal-title":"Psychopharmacology"},{"key":"12576_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/157488612800492726","volume":"7","author":"M Raja","year":"2012","unstructured":"Raja M, Bentivoglio AR (2012) Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson\u2019s Disease and other disorders. Curr Drug Saf 7:63\u201375. https:\/\/doi.org\/10.2174\/157488612800492726","journal-title":"Curr Drug Saf"},{"key":"12576_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.parkreldis.2011.03.003","volume":"17","author":"CW Hicks","year":"2011","unstructured":"Hicks CW, Pandya MM, Itin I, Fernandez HH (2011) Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 17:379\u2013381. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.03.003","journal-title":"Parkinsonism Relat Disord"},{"key":"12576_CR49","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1212\/WNL.0b013e3182840678","volume":"80","author":"D Okai","year":"2013","unstructured":"Okai D, Askey-Jones S, Samuel M, O\u2019Sullivan SS, Chaudhuri KR, Martin A, Mack J, Brown RG, David AS (2013) Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 80:792\u2013799. https:\/\/doi.org\/10.1212\/WNL.0b013e3182840678","journal-title":"Neurology"},{"key":"12576_CR50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.parkreldis.2015.03.003","volume":"21","author":"A Alexoudi","year":"2015","unstructured":"Alexoudi A, Shalash A, Knudsen K, Witt K, Mehdorn M, Volkmann J, Deuschl G (2015) The medical treatment of patients with Parkinson\u2019s disease receiving subthalamic neurostimulation. Parkinsonism Relat Disord 21:555\u2013560. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.03.003. (discussion 555)","journal-title":"Parkinsonism Relat Disord"},{"key":"12576_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrneurol.2010.111","volume":"6","author":"J Volkmann","year":"2010","unstructured":"Volkmann J, Daniels C, Witt K (2010) Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 6:487\u2013498. https:\/\/doi.org\/10.1038\/nrneurol.2010.111","journal-title":"Nat Rev Neurol"},{"key":"12576_CR52","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/brain\/aws078","volume":"135","author":"E Lhommee","year":"2012","unstructured":"Lhommee E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, Kistner A, Fraix V, Xie J, Aya Kombo M, Chabardes S, Seigneuret E, Benabid AL, Mertens P, Polo G, Carnicella S, Quesada JL, Bosson JL, Broussolle E, Pollak P, Krack P (2012) Subthalamic stimulation in Parkinson\u2019s disease: restoring the balance of motivated behaviours. Brain 135:1463\u20131477. https:\/\/doi.org\/10.1093\/brain\/aws078","journal-title":"Brain"},{"key":"12576_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jnnp-2012-302444","volume":"84","author":"A Castrioto","year":"2013","unstructured":"Castrioto A, Kistner A, Klinger H, Lhomm\u00e9e E, Schmitt E, Fraix V, Chabard\u00e8s S, Mertens P, Quesada JL, Broussolle E, Pollak P, Thobois SC, Krack P (2013) Psychostimulant effect of levodopa: reversing sensitisation is possible. J Neurol Neurosurg Psychiatry 84:18\u201322. https:\/\/doi.org\/10.1136\/jnnp-2012-302444","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12576_CR54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s1474-4422(18)30035-8","volume":"17","author":"E Lhomm\u00e9e","year":"2018","unstructured":"Lhomm\u00e9e E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, H\u00e4lbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-D\u00f6ring F, Kupsch A, Kr\u00fcger R, Elben S, Chabard\u00e8s S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis JM, Malt\u00eate D, Sauvaget A, Rau J, Schnitzler A, Sch\u00fcpbach M, Schade-Brittinger C, Deuschl G, Houeto JL, Krack P (2018) Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson\u2019s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol 17:223\u2013231. https:\/\/doi.org\/10.1016\/s1474-4422(18)30035-8","journal-title":"Lancet Neurol"},{"key":"12576_CR55","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/ana.21795","volume":"66","author":"B Ballanger","year":"2009","unstructured":"Ballanger B, van Eimeren T, Moro E, Lozano AM, Hamani C, Boulinguez P, Pellecchia G, Houle S, Poon YY, Lang AE, Strafella AP (2009) Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol 66:817\u2013824. https:\/\/doi.org\/10.1002\/ana.21795","journal-title":"Ann Neurol"},{"key":"12576_CR56","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.parkreldis.2006.01.004","volume":"12","author":"Y Temel","year":"2006","unstructured":"Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V (2006) Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat Disord 12:265\u2013272. https:\/\/doi.org\/10.1016\/j.parkreldis.2006.01.004","journal-title":"Parkinsonism Relat Disord"},{"key":"12576_CR57","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/archneur.63.2.298-a","volume":"63","author":"C Lu","year":"2006","unstructured":"Lu C, Bharmal A, Suchowersky O (2006) Gambling and Parkinson disease. Arch Neurol 63:298. https:\/\/doi.org\/10.1001\/archneur.63.2.298-a","journal-title":"Arch Neurol"},{"key":"12576_CR58","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/mds.20501","volume":"20","author":"T Witjas","year":"2005","unstructured":"Witjas T, Baunez C, Henry JM, Delfini M, Regis J, Cherif AA, Peragut JC, Azulay JP (2005) Addiction in Parkinson\u2019s disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 20:1052\u20131055. https:\/\/doi.org\/10.1002\/mds.20501","journal-title":"Mov Disord"},{"key":"12576_CR59","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/jnnp.72.6.701","volume":"72","author":"JL Houeto","year":"2002","unstructured":"Houeto JL, Mesnage V, Mallet L, Pillon B, Gargiulo M, du Moncel ST, Bonnet AM, Pidoux B, Dormont D, Cornu P, Agid Y (2002) Behavioural disorders, Parkinson\u2019s disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 72:701\u2013707. https:\/\/doi.org\/10.1136\/jnnp.72.6.701","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12576_CR60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.parkreldis.2011.02.013","volume":"17","author":"M Broen","year":"2011","unstructured":"Broen M, Duits A, Visser-Vandewalle V, Temel Y, Winogrodzka A (2011) Impulse control and related disorders in Parkinson\u2019s disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord 17:413\u2013417. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.02.013","journal-title":"Parkinsonism Relat Disord"},{"key":"12576_CR61","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/mds.25735","volume":"28","author":"MS Okun","year":"2013","unstructured":"Okun MS, Weintraub D (2013) Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? Mov Disord 28:1915\u20131919. https:\/\/doi.org\/10.1002\/mds.25735","journal-title":"Mov Disord"},{"key":"12576_CR62","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/jnnp-2017-316373","volume":"89","author":"M Abbes","year":"2018","unstructured":"Abbes M, Lhommee E, Thobois S, Klinger H, Schmitt E, Bichon A, Castrioto A, Xie J, Fraix V, Kistner A, Pelissier P, Seigneuret E, Chabardes S, Mertens P, Broussolle E, Moro E, Krack P (2018) Subthalamic stimulation and neuropsychiatric symptoms in Parkinson\u2019s disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatry 89:836\u2013843. https:\/\/doi.org\/10.1136\/jnnp-2017-316373","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12576_CR63","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/mds.21098","volume":"21","author":"C Ardouin","year":"2006","unstructured":"Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, Hosseini H, Pelissolo A, Moro E, Lhommee E, Lang AE, Agid Y, Benabid AL, Pollak P, Mallet L, Krack P (2006) Pathological gambling in Parkinson\u2019s disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21:1941\u20131946. https:\/\/doi.org\/10.1002\/mds.21098","journal-title":"Mov Disord"},{"key":"12576_CR64","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/WNN.0b013e318185e6e2","volume":"21","author":"D Knobel","year":"2008","unstructured":"Knobel D, Aybek S, Pollo C, Vingerhoets FJ, Berney A (2008) Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report. Cogn Behav Neurol 21:187\u2013189. https:\/\/doi.org\/10.1097\/WNN.0b013e318185e6e2","journal-title":"Cogn Behav Neurol"},{"key":"12576_CR65","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.parkreldis.2006.07.011","volume":"13","author":"F Bandini","year":"2007","unstructured":"Bandini F, Primavera A, Pizzorno M, Cocito L (2007) Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson\u2019s disease. Parkinsonism Relat Disord 13:369\u2013371. https:\/\/doi.org\/10.1016\/j.parkreldis.2006.07.011","journal-title":"Parkinsonism Relat Disord"},{"key":"12576_CR66","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/mds.28320","volume":"36","author":"MDN Santin","year":"2021","unstructured":"Santin MDN, Voulleminot P, Vrillon A, Hainque E, Bereau M, Lagha-Boukbiza O, Wirth T, Montaut S, Bardinet E, Kyheng M, Rolland AS, Voirin J, Drapier S, Durif F, Eusebio A, Giordana C, Auzou N, Houeto JL, Hubsch C, Jarraya B, Laurencin C, Maltete D, Meyer M, Rascol O, Rouaud T, Tir M, Moreau C, Corvol JC, Proust F, Grabli D, Devos D, Tranchant C, Anheim M, Predistim Study G (2021) Impact of subthalamic deep brain stimulation on impulse control disorders in Parkinson\u2019s disease: a prospective study. Mov Disord 36:750\u2013757. https:\/\/doi.org\/10.1002\/mds.28320","journal-title":"Mov Disord"},{"key":"12576_CR67","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/brain\/awq032","volume":"133","author":"S Thobois","year":"2010","unstructured":"Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P (2010) Non-motor dopamine withdrawal syndrome after surgery for Parkinson\u2019s disease: predictors and underlying mesolimbic denervation. Brain 133:1111\u20131127. https:\/\/doi.org\/10.1093\/brain\/awq032","journal-title":"Brain"},{"key":"12576_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00702-015-1400-x","volume":"123","author":"J Levin","year":"2016","unstructured":"Levin J, Hasan A, Hoglinger GU (2016) Psychosis in Parkinson\u2019s disease: identification, prevention and treatment. J Neural Transm (Vienna) 123:45\u201350. https:\/\/doi.org\/10.1007\/s00702-015-1400-x","journal-title":"J Neural Transm (Vienna)"},{"key":"12576_CR69","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00115-015-4438-y","volume":"87","author":"R Haussmann","year":"2016","unstructured":"Haussmann R, Bauer M, Donix M (2016) Evidence-based treatment of psychosis associated with Parkinson\u2019s disease. Nervenarzt 87:543\u2013551. https:\/\/doi.org\/10.1007\/s00115-015-4438-y","journal-title":"Nervenarzt"},{"key":"12576_CR70","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40266-016-0416-8","volume":"33","author":"N Samudra","year":"2016","unstructured":"Samudra N, Patel N, Womack KB, Khemani P, Chitnis S (2016) Psychosis in Parkinson disease: a review of etiology, phenomenology, and management. Drugs Aging 33:855\u2013863. https:\/\/doi.org\/10.1007\/s40266-016-0416-8","journal-title":"Drugs Aging"},{"key":"12576_CR71","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","volume":"13","author":"DH Ffytche","year":"2017","unstructured":"Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D (2017) The psychosis spectrum in Parkinson disease. Nat Rev Neurol 13:81\u201395. https:\/\/doi.org\/10.1038\/nrneurol.2016.200","journal-title":"Nat Rev Neurol"},{"key":"12576_CR72","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1055\/a-1670-7111","volume":"90","author":"D Weiss","year":"2022","unstructured":"Weiss D, Hoglinger G, Klostermann F, Weise D, Zeuner KE, Reichmann H (2022) Hallucinations in patients with idiopathic Parkinson\u2019s disease. Fortschr Neurol Psychiatr 90:456\u2013464. https:\/\/doi.org\/10.1055\/a-1670-7111","journal-title":"Fortschr Neurol Psychiatr"},{"key":"12576_CR73","doi-asserted-by":"publisher","first-page":"3469706","DOI":"10.1155\/2021\/3469706","volume":"2021","author":"M Zhong","year":"2021","unstructured":"Zhong M, Gu R, Zhu S, Bai Y, Wu Z, Jiang X, Shen B, Zhu J, Pan Y, Yan J, Zhang L (2021) Prevalence and risk factors for minor hallucinations in patients with Parkinson\u2019s disease. Behav Neurol 2021:3469706. https:\/\/doi.org\/10.1155\/2021\/3469706","journal-title":"Behav Neurol"},{"key":"12576_CR74","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/ane.13380","volume":"143","author":"S Omoto","year":"2021","unstructured":"Omoto S, Murakami H, Shiraishi T, Bono K, Umehara T, Iguchi Y (2021) Risk factors for minor hallucinations in Parkinson\u2019s disease. Acta Neurol Scand 143:538\u2013544. https:\/\/doi.org\/10.1111\/ane.13380","journal-title":"Acta Neurol Scand"},{"key":"12576_CR75","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/brain\/awaa413","volume":"144","author":"G Naasan","year":"2021","unstructured":"Naasan G, Shdo SM, Rodriguez EM, Spina S, Grinberg L, Lopez L, Karydas A, Seeley WW, Miller BL, Rankin KP (2021) Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms. Brain 144:999\u20131012. https:\/\/doi.org\/10.1093\/brain\/awaa413","journal-title":"Brain"},{"key":"12576_CR76","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11065-018-9379-3","volume":"28","author":"N Warren","year":"2018","unstructured":"Warren N, O\u2019Gorman C, Hume Z, Kisely S, Siskind D (2018) Delusions in Parkinson\u2019s disease: a systematic review of published cases. Neuropsychol Rev 28:310\u2013316. https:\/\/doi.org\/10.1007\/s11065-018-9379-3","journal-title":"Neuropsychol Rev"},{"key":"12576_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117206","volume":"419","author":"B Cravanas Jr","year":"2020","unstructured":"Cravanas B Jr, Frei K (2020) The effects of Cannabis on hallucinations in Parkinson\u2019s disease patients. J Neurol Sci 419:117206. https:\/\/doi.org\/10.1016\/j.jns.2020.117206","journal-title":"J Neurol Sci"},{"key":"12576_CR78","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/00207454.2020.1821678","volume":"132","author":"J Greger","year":"2022","unstructured":"Greger J, Aladeen T, Rainka M, Kale A, Capote H (2022) Evaluating rates of reporting symptoms of Parkinson\u2019s disease psychosis: provider versus targeted questionnaire. Int J Neurosci 132:459\u2013465. https:\/\/doi.org\/10.1080\/00207454.2020.1821678","journal-title":"Int J Neurosci"},{"key":"12576_CR79","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"B Ravina","year":"2007","unstructured":"Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C (2007) Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061\u20131068. https:\/\/doi.org\/10.1002\/mds.21382","journal-title":"Mov Disord"},{"key":"12576_CR80","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/mds.21875","volume":"23","author":"HH Fernandez","year":"2008","unstructured":"Fernandez HH, Aarsland D, Fenelon G, Friedman JH, Marsh L, Troster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG (2008) Scales to assess psychosis in Parkinson\u2019s disease: critique and recommendations. Mov Disord 23:484\u2013500. https:\/\/doi.org\/10.1002\/mds.21875","journal-title":"Mov Disord"},{"key":"12576_CR81","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/14737175.2021.1851198","volume":"22","author":"A Powell","year":"2022","unstructured":"Powell A, Matar E, Lewis SJG (2022) Treating hallucinations in Parkinson\u2019s disease. Expert Rev Neurother 22:455\u2013468. https:\/\/doi.org\/10.1080\/14737175.2021.1851198","journal-title":"Expert Rev Neurother"},{"key":"12576_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2257","volume":"11","author":"TJM van Mierlo","year":"2021","unstructured":"van Mierlo TJM, Foncke EMJ, Post B, Schmand BA, Bloem BR, van Harten B, Tissingh G, Munts AG, de Haan RJ, de Bie RMA, other individuals of the CSG (2021) Rivastigmine for minor visual hallucinations in Parkinson\u2019s disease: A randomized controlled trial with 24 months follow-up. Brain Behav 11:e2257. https:\/\/doi.org\/10.1002\/brb3.2257","journal-title":"Brain Behav"},{"key":"12576_CR83","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/08919887231154933","volume":"36","author":"I Yunusa","year":"2023","unstructured":"Yunusa I, Rashid N, Seyedin R, Paratane D, Rajagopalan K (2023) Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson\u2019s disease psychosis: systematic review and network meta-analysis. J Geriatr Psychiatry Neurol 36:417\u2013432. https:\/\/doi.org\/10.1177\/08919887231154933","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"12576_CR84","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","volume":"11","author":"E Wagner","year":"2021","unstructured":"Wagner E, Siafis S, Fernando P, Falkai P, Honer WG, Roh A, Siskind D, Leucht S, Hasan A (2021) Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. Transl Psychiatry 11:487. https:\/\/doi.org\/10.1038\/s41398-021-01613-2","journal-title":"Transl Psychiatry"},{"key":"12576_CR85","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1212\/CPJ.0000000000000342","volume":"7","author":"T Hawkins","year":"2017","unstructured":"Hawkins T, Berman BD (2017) Pimavanserin: a novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract 7:157\u2013162. https:\/\/doi.org\/10.1212\/CPJ.0000000000000342","journal-title":"Neurol Clin Pract"},{"key":"12576_CR86","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/mds.28335","volume":"36","author":"A Takamiya","year":"2021","unstructured":"Takamiya A, Seki M, Kudo S, Yoshizaki T, Nakahara J, Mimura M, Kishimoto T (2021) Electroconvulsive therapy for Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 36:50\u201358. https:\/\/doi.org\/10.1002\/mds.28335","journal-title":"Mov Disord"},{"key":"12576_CR87","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/S0140-6736(14)60994-6","volume":"383","author":"SK Inouye","year":"2014","unstructured":"Inouye SK, Westendorp RG, Saczynski JS, Kimchi EY, Cleinman AA (2014) Delirium in elderly people\u2013authors\u2019reply. Lancet 383:2045. https:\/\/doi.org\/10.1016\/S0140-6736(14)60994-6","journal-title":"Lancet"},{"key":"12576_CR88","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00702-019-01980-7","volume":"126","author":"G Ebersbach","year":"2019","unstructured":"Ebersbach G, Ip CW, Klebe S, Koschel J, Lorenzl S, Schrader C, Winkler C, Franke C (2019) Management of delirium in Parkinson\u2019s disease. J Neural Transm (Vienna) 126:905\u2013912. https:\/\/doi.org\/10.1007\/s00702-019-01980-7","journal-title":"J Neural Transm (Vienna)"},{"key":"12576_CR89","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00115-020-00876-2","volume":"91","author":"C Franke","year":"2020","unstructured":"Franke C, Ebersbach G (2020) Delirium in idiopathic Parkinson\u2019s disease. Nervenarzt 91:107\u2013113. https:\/\/doi.org\/10.1007\/s00115-020-00876-2","journal-title":"Nervenarzt"},{"key":"12576_CR90","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.parkreldis.2018.09.025","volume":"64","author":"RA Lawson","year":"2019","unstructured":"Lawson RA, McDonald C, Burn DJ (2019) Defining delirium in idiopathic Parkinson\u2019s disease: a systematic review. Parkinsonism Relat Disord 64:29\u201339. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.09.025","journal-title":"Parkinsonism Relat Disord"},{"key":"12576_CR91","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jpainsymman.2004.07.009","volume":"29","author":"JD Gaudreau","year":"2005","unstructured":"Gaudreau JD, Gagnon P, Harel F, Tremblay A, Roy MA (2005) Fast, systematic, and continuous delirium assessment in hospitalized patients: the nursing delirium screening scale. J Pain Symptom Manage 29:368\u2013375. https:\/\/doi.org\/10.1016\/j.jpainsymman.2004.07.009","journal-title":"J Pain Symptom Manage"},{"key":"12576_CR92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1891\/rtnp.17.1.31.53169","volume":"17","author":"MJ Schuurmans","year":"2003","unstructured":"Schuurmans MJ, Shortridge-Baggett LM, Duursma SA (2003) The Delirium Observation Screening Scale: a screening instrument for delirium. Res Theory Nurs Pract 17:31\u201350. https:\/\/doi.org\/10.1891\/rtnp.17.1.31.53169","journal-title":"Res Theory Nurs Pract"},{"key":"12576_CR93","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/07853890009011770","volume":"32","author":"SK Inouye","year":"2000","unstructured":"Inouye SK (2000) Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. Ann Med 32:257\u2013263. https:\/\/doi.org\/10.3109\/07853890009011770","journal-title":"Ann Med"},{"key":"12576_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3704","volume":"341","author":"J Young","year":"2010","unstructured":"Young J, Murthy L, Westby M, Akunne A, O\u2019Mahony R, Guideline Development G (2010) Diagnosis, prevention, and management of delirium: summary of NICE guidance. BMJ 341:c3704. https:\/\/doi.org\/10.1136\/bmj.c3704","journal-title":"BMJ"},{"key":"12576_CR95","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00415-015-7760-1","volume":"262","author":"ER Vardy","year":"2015","unstructured":"Vardy ER, Teodorczuk A, Yarnall AJ (2015) Review of delirium in patients with Parkinson\u2019s disease. J Neurol 262:2401\u20132410. https:\/\/doi.org\/10.1007\/s00415-015-7760-1","journal-title":"J Neurol"},{"key":"12576_CR96","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","volume":"168","author":"JL Rudolph","year":"2008","unstructured":"Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168:508\u2013513. https:\/\/doi.org\/10.1001\/archinternmed.2007.106","journal-title":"Arch Intern Med"},{"key":"12576_CR97","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.psym.2018.05.011","volume":"60","author":"J Riviere","year":"2019","unstructured":"Riviere J, van der Mast RC, Vandenberghe J, Van Den Eede F (2019) Efficacy and tolerability of atypical antipsychotics in the treatment of delirium: a systematic review of the literature. Psychosomatics 60:18\u201326. https:\/\/doi.org\/10.1016\/j.psym.2018.05.011","journal-title":"Psychosomatics"},{"key":"12576_CR98","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1212\/wnl.0000000000007942","volume":"93","author":"F Baig","year":"2019","unstructured":"Baig F, Kelly MJ, Lawton MA, Ruffmann C, Rolinski M, Klein JC, Barber T, Lo C, Ben-Shlomo Y, Okai D, Hu MT (2019) Impulse control disorders in Parkinson disease and RBD: a longitudinal study of severity. Neurology 93:e675\u2013e687. https:\/\/doi.org\/10.1212\/wnl.0000000000007942","journal-title":"Neurology"},{"key":"12576_CR99","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jns.2016.12.070","volume":"374","author":"XX Yu","year":"2017","unstructured":"Yu XX, Fernandez HH (2017) Dopamine agonist withdrawal syndrome: a comprehensive review. J Neurol Sci 374:53\u201355. https:\/\/doi.org\/10.1016\/j.jns.2016.12.070","journal-title":"J Neurol Sci"},{"key":"12576_CR100","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ana.26434","volume":"92","author":"S Prange","year":"2022","unstructured":"Prange S, Lin Z, Nourredine M, Danaila T, Laurencin C, Lagha-Boukbiza O, Anheim M, Klinger H, Longato N, Phillipps C, Voirin J, Polo G, Simon E, Mertens P, Rolland AS, Devos D, Metereau E, Tranchant C, Thobois S (2022) Limbic stimulation drives mania in STN-DBS in Parkinson disease: a prospective study. Ann Neurol 92:411\u2013417. https:\/\/doi.org\/10.1002\/ana.26434","journal-title":"Ann Neurol"},{"key":"12576_CR101","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, B\u00e4ckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394:939\u2013951. https:\/\/doi.org\/10.1016\/s0140-6736(19)31135-3","journal-title":"Lancet"},{"key":"12576_CR102","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A (2021) Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med 384:717\u2013726. https:\/\/doi.org\/10.1056\/NEJMoa2017015","journal-title":"N Engl J Med"},{"key":"12576_CR103","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK (2024) Efficacy and safety of Xanomeline-Trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiat. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0785","journal-title":"JAMA Psychiat"},{"key":"12576_CR104","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/s0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2022","unstructured":"Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J (2022) Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet 400:2210\u20132220. https:\/\/doi.org\/10.1016\/s0140-6736(22)01990-0","journal-title":"Lancet"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12576-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12576-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12576-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T14:04:17Z","timestamp":1732543457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12576-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":104,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["12576"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12576-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.W. has received funding from the Deutsche Forschungsgemeinschaft (German Research Association) and STADAPHARM GmbH outside the present study. He has received honoraria for presentations\/advisory boards\/consultations from BIAL, Indorsia, Boston Scientific and STADAPHARM GmbH, outside the present study. He has received royalties from Thieme Press and Elsevier Press. He serves as an editorial board member of Wileys \u201cParkinson\u2019s Disease\u201d, \u201cBehavioural Neurology\u201d and PLOSone. J.L. reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA, Zambon, Esteve, Merck and Roche; consulting fees from Axon Neuroscience, EISAI and Biogen; author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent \u201cOral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies\u201d (PCT\/EP2024\/053388) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share programme of MODAG GmbH and is inventor in a patent \u201cPharmaceutical Composition and Methods of Use\u201d (EP 22 159 408.8) filed by MODAG GmbH, all activities outside the submitted work. T.v.E. received funding from the German Research Foundation (DFG) and the Brandau-Laibach Stiftung. He received honoraria for consulting and advisory work from Lundbeck Foundation and Lundbeck Pharma, Orion Pharma, GT Gain Therapeutics SA and ICON. He received materials from Life Molecular Imaging and Lilly. He owns stocks in NVIDIA, Microsoft and I.B.M. A.H. was a member of advisory boards of Boehringer Ingelheim, Lundbeck, Janssen, Otsuka, Rovi and Recordati and received paid speakership by these companies as well as by AbbVie and Advanz. He is editor of the German schizophrenia guideline. G.E. has received honoraria for presentations (advisory boards\/consultations) from AbbVie Pharma, BIAL Pharma, Boehringer GmbH, Britannia Pharma, Desitin Pharma, ESTEVE Pharma, Neuraxpharm GmbH, STADAPHARMA GmbH and Zambon Pharma. He has received royalties from Kohlhammer Press and Thieme Press.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}